Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 101

Results For "Import"

1694 News Found

Apollo Education UK launches the Apollo International Clinical Fellowship Programme
News | June 29, 2022

Apollo Education UK launches the Apollo International Clinical Fellowship Programme

Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.


R&D key for the growth of nation: Dr. Mandaviya
Policy | June 28, 2022

R&D key for the growth of nation: Dr. Mandaviya

The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.


50%+ patients delay cataract surgeries in India: Survey
Public Health | June 28, 2022

50%+ patients delay cataract surgeries in India: Survey

73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries


Pharma industry warming up towards adoption of digital technologies
Digitisation | June 27, 2022

Pharma industry warming up towards adoption of digital technologies

By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities


ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
Drug Approval | June 24, 2022

ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP

ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.


Rivaroxaban approved in Japan for patients with PAD after revascularisation
Drug Approval | June 24, 2022

Rivaroxaban approved in Japan for patients with PAD after revascularisation

It´s the first trial to demonstrate the benefits of dual pathway inhibition


Indian Pharma Post organizes e-Conference on ‘Role of Digitalization in Pharma Sector’  June 24
Digitisation | June 23, 2022

Indian Pharma Post organizes e-Conference on ‘Role of Digitalization in Pharma Sector’ June 24

Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers


Merck presents positive results from phase 1/2 study evaluating V116
News | June 22, 2022

Merck presents positive results from phase 1/2 study evaluating V116

V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019


AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
News | June 22, 2022

AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza

LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)


Medix Biochemica acquires Bioresource Technology
News | June 21, 2022

Medix Biochemica acquires Bioresource Technology

Bioresource Technology's state of the art manufacturing facility in Weston, Florida